EDITORIAL SECTION

Articles

Radical Optionality to Leadership Reinvention: Dual Framework for Biotech-CDMO Transformation

Biotech and CDMOs stand at a pivotal crossroads On one side scientific complexity is acceleratingnew modalities such as antibodydrug conjugates mRNA oligonucleotides and cell and gene therapies demand faster more adaptive development models On the other side systemic pressures are tighteningthe biotech funding squeeze the Biosecure Act and fractured global supply chains are forcing organisations t...

Single-Use Technologies: Accelerating Flexible Biopharmaceutical Manufacturing

For most of the past two decades the case for singleuse technologies in biopharmaceutical manufacturing was argued in the language of the plant Disposable bags and flow paths removed cleaninplace and steaminplace loops shortened turnarounds and allowed engineers to stand up a suite without a validation campaign measured in seasons That argument has been won Disposable systems now appear at every s...

Circular Logistics: A Strategic Advantage for U.S. Pharmaceutical Supply Chains in an Era of Uncertainty

Temperaturerelated failures are estimated to cost the industry billion annually highlighting a nonnegotiable requirement for reliability product integrity and regulatory compliance For manufacturers

B2B Pharma Editorial Opportunities: Boosting Brand Visibility in Industry Magazines

The teams which previously counted greatly on banner advertisements email newsletters and sponsorship of various events are beginning to reevaluate the source of true influence Since such channels have a role to play they seldom earn credibility alone In contrast a wellplaced article in a respected industry publication can do something most campaigns struggle to achieveit makes people take you ser...

Pharmaceutical Market Access and Reimbursement Strategies in Europe

Getting EMA approval is a milestone but it isnt a launch In Europe a medicine can be authorized in every member state and still not reach a single patient until each country agrees on its price and who pays for it That gap between approval and access is where pharmaceutical market access is won or lost

Advertise Smarter with the 2025 Pharma Focus Europe Media Pack

The internet has forever changed the healthcare industry and it is no longer whether to advertise but how to advertise better in the changing digital world Following the shift of pharma marketing to precision personalization and performance Pharma Focus Europe Media Pack is precisely your prescription to be the best in terms of competing in the European market

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys